50% of the Revenue Contribution by the Leading Players
The hypoparathyroidism treatment market is largely dominated by the major players, who are competing on the basis of market penetration and distribution. The consolidated nature of the hypoparathyroidism treatment market increases the profitability. Factors such as poor efficacy and efficiency of the treatment are hampering the adoption of hypoparathyroidism treatment.
However, the growing awareness regarding hypoparathyroidism treatment and number of thyroid surgeries are expected to create growth opportunities for the manufacturers operating in the global hypoparathyroidism treatment market. Shire-NPS Pharmaceuticals, Inc., EnteraBio Ltd., and Teva Pharmaceutical Industries Ltd. hold more than 50% revenue share in the global hypoparathyroidism treatment market.
The growth of the global hypoparathyroidism treatment market is primarily driven by growing prevalence of hypoparathyroidism and increasing number of thoracic surgeries and incidence of cancer. The development of healthcare infrastructure across the globe coupled with governmental support for hypoparathyroidism treatment is expected to drive the growth of the hypoparathyroidism treatment market. The companies operating in the market are involved in developing new experimental hypoparathyroidism treatment drugs.
Increasing Number of Thoracic Surgeries and Incidence of Cancer
The growing screening rates, increasing number of thoracic surgeries and incidence of cancer are expected to be the prime factors driving the growth of the hypoparathyroidism treatment market. Thyroid or neck surgery is associated with hypoparathyroidism, owing to damage to the parathyroid glands. The number of thyroidectomies in the U.S. reflects 39% increase from 2007 to 2015.
This indicates transient post-surgical hypoparathyroidism, which can become permanent in about 25% of cases. The growing incidence of head & neck and thyroid cancers is the other factor expected to drive the growth of the market.
Increasing investments in the research and development coupled with the development of biologics is expected to generate momentum and growth opportunities for the hypoparathyroidism treatment market.
New Drug Development and Government Support to Root Out Hypoparathyroidism
New drug development is expected to create enormous growth opportunity for the hypoparathyroidism treatment market. Any new curative hypoparathyroidism treatment drug is expected to witness fast adoption with minimal resources due to lack of competition in the hypoparathyroidism treatment market. Symptomatic treatment is the chief goal of hypoparathyroidism treatment as there is no treatment for hypoparathyroidism.
The support to hypoparathyroidism treatment products and initiatives by the governments of different countries such as financial incentives and orphan status are the other factors expected to boost the growth of the hypoparathyroidism treatment market. The demographic drivers of the hypoparathyroidism treatment market include growing geriatric population and healthcare expenditure across the globe.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Growing Purchasing Power and Attractive Reimbursements
In the North America hypoparathyroidism treatment market, the U.S. is expected to be the dominant country as it is a large economy and with high purchasing power. Besides, favorable reimbursements for hypoparathyroidism treatment is also expected to support the growth of the hypoparathyroidism market.
Likewise, large presence of major players such as Shire-NPS Pharmaceuticals, Inc., and EnteraBio Ltd., among others, is also expected to drive the growth of the hypoparathyroidism treatment market in the U.S. The healthcare expenditure in the U.S. was almost 16% of its GDP in 2017, which reflects better pricing and market attractiveness for the hypoparathyroidism treatment market.
Orphan Status and Incentives
The U.S. FDA’s orphan status to drugs and biologics that affect less than 200,000 people in the U.S. confer various incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval. In the hypoparathyroidism treatment market, Natpara is an approved drug with a black box warning notified by the U.S. FDA in January 2015 – enjoying an exclusivity period till 2022.
This section of the report features the profiles of the key players in the hypoparathyroidism treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. The key players operating in the hypoparathyroidism treatment market include Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and EnteraBio Ltd.
Hypoparathyroidism is the decreased secretion or activity of parathyroid hormone (PTH) resulting in low blood levels of calcium and higher levels of blood phosphorus
About the Report
FMI conducted a research study on hypoparathyroidism treatment market for the forecast period 2018 to 2022. The hypoparathyroidism treatment market report offers a comprehensive evaluation of the business opportunities prevailing in the hypoparathyroidism treatment market along with insights on the hypoparathyroidism treatment consumption trend, disease incidences, and awareness level for hypoparathyroidism treatment market competition. The report elaborates the macroeconomic factors influencing the dynamics of hypoparathyroidism treatment market and its futuristic potential.
Additional Questions Answered
Some of the additional questions addressed in this report on hypoparathyroidism treatment market-
- What is the revenue potential of the hypoparathyroidism treatment market across regions of North America and Europe?
- Who are the key competitors and what are their portfolios in hypoparathyroidism treatment market?
- What are major challenges influencing the growth of hypoparathyroidism treatment market?
- How intervention from regulatory authority is shaping the hypoparathyroidism treatment market growth?
The hypoparathyroidism treatment market has been estimated based on supply-demand approach. The market was first calculated based on incidence and diagnosis rate, conducted in different region/countries. Other qualitative factors analyzed during the estimation include treatment rates for hypoparathyroidism treatment, recurrence rate and others.
This information is further validated with rigorous primary research (including in-person interactions, interviews, surveys and viewpoints of seasoned analysts) and secondary research (including resourceful databases, verified paid sources, and authentic trade journals).
The research study on hypoparathyroidism treatment market also includes top trends and macro as well as micro economic factors shaping the hypoparathyroidism treatment market. With this approach, the report on hypoparathyroidism treatment market anticipates the industry attractiveness of every major segment in hypoparathyroidism treatment over the forecast period.
The report offers a comprehensive taxonomy of hypoparathyroidism treatment market based on drug class, route of administration, distribution channels and region. The drug class segment of the hypoparathyroidism treatment market includes parathyroid hormone, vitamin D analogue and calcium supplements. The route of administration segment of the hypoparathyroidism treatment market includes oral, and parenteral. The distribution channel segment of the hypoparathyroidism treatment market includes retail pharmacy, hospital pharmacy and online sales.
The hypoparathyroidism treatment market has been analyzed across regions of North America, Latin America, Europe, Asia Pacific and MEA.